PARM1-AS1: A Potential Drug Target and Biomarker (G100507388)

Target Name: PARM1-AS1

NCBI ID: G100507388

PARM1-AS1

Other Name(s): PARM1 antisense RNA 1

PARM1-AS1: A Potential Drug Target and Biomarker

PARM1 (Perinodermal Artery Regeneration Model 1) and AS1 (Angiogenesis Survival) are two genes that have been identified as potential drug targets and biomarkers for the treatment of a variety of diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. These genes have been shown to play important roles in the regulation of angiogenesis, the formation of new blood vessels, and the survival of tissues.

The PARM1 gene is a member of the TGF-β pathway, a well-known signaling pathway that regulates cellular growth, differentiation, and survival. The PARM1 gene has been shown to be involved in the regulation of angiogenesis, with studies demonstrating that it plays a role in the formation of new blood vessels and the growth of tissues.

The AS1 gene is closely related to the PARM1 gene and has also been shown to be involved in the regulation of angiogenesis. Studies have shown that AS1 is involved in the formation of new blood vessels and that it plays a role in the development of various diseases, including cancer.

The potential drug targets for PARM1 and AS1 are vast and varied. In cancer, PARM1 and AS1 have been shown to be involved in the regulation of angiogenesis, which is thought to contribute to the development and progression of many types of cancer. As such, these genes may be useful targets for the development of new cancer therapies.

In neurodegenerative disorders, PARM1 and AS1 have been shown to be involved in the regulation of the formation of new blood vessels and the growth of tissues, which may contribute to the development and progression of these disorders. As such, these genes may be useful targets for the development of new therapies for neurodegenerative disorders.

In cardiovascular diseases, PARM1 and AS1 have been shown to be involved in the regulation of angiogenesis, which is thought to contribute to the development and progression of many types of cardiovascular diseases. As such, these genes may be useful targets for the development of new therapies for cardiovascular diseases.

The potential uses of PARM1 and AS1 as drug targets and biomarkers are vast and varied. While more research is needed to fully understand the role of these genes in the development and progression of diseases, they have the potential to be valuable tools for the development of new therapies for a variety of diseases.

Overall, the PARM1 and AS1 genes have the potential to be valuable drug targets and biomarkers for the treatment of a variety of diseases. Further research is needed to fully understand their role in the development and progression of these diseases and to develop new therapies based on them.

Protein Name: PARM1 Antisense RNA 1

The "PARM1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARM1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets